This measure would calculate the rate of cases where actionable biomarkers for targeted therapy are identified through repeat molecular tests ordered by the provider due to inadequate tissue samples (as determined by the pathologist or receiving physician) for patients with Stage IV NSCLC and…
Associated with Clinicians Office
eCQM Concept -
In alignment with NCCN guidelines,[1] this measure would calculate the percentage of patients with Stage IV NSCLC and established histological subtypes who receive biomarker/molecular testing for a broad panel of actionable biomarkers as their initial genomic test as opposed to single gene testing…
eCQM Concept -
This measure would calculate the percentage of patients with a cancer diagnosis and/or increased risk of high-burden cancers (NSCLC, breast, colorectal, cervical, prostate) eligible for guideline-recommended biomarker/molecular testing options who (1) were screened for the 5 domains of social…